EyePoint Pharmaceuticals, Inc. — Director's Dealing 2020

Feb 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-02-21

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-21	Common Stock	M	137174.00	$0.00	Acquired	476800.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-21	Restricted Stock Units	$0.00	M	137174.00	Disposed		Common Stock (137174.00)	Direct

Footnotes

F1: Includes 25,171 shares acquired on January 31, 2020 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: The restricted stock units vest in three ratable annual installments beginning February 21, 2020.